| | References | Study, cohort, or first author name | Drugs studied | Study design | Number of RA patients | Endpoint |
| | [6] | Chen | ADA, ETN | Cohort | 48 | 6-month EULAR response | | [7] | Kleinert | ADA | Noninterventional study | 2,625 | 12-month DAS28 variation | | [8] | ReAct | ADA | Open-label study | 6,610 | 12-week DAS28 remission | | [9] | TEMPO | ETN | Randomized controlled double-blind study (MTX or ETN or MTX + ETN) | 682 | 3-year DAS28 remission | | [10] | BSRBR | IFX and ETN | Prospective registry | 2,879 | 6-month EULAR response | | [11] | GISEA | IFX, ADA, ETN | Retrospective registry | 1,565 | 3-month EULAR response | | [12] | REACTION | TCZ | Multicenter retrospective study | 229 | 24-week EULAR response and DAS28 remission | | [13] | DANBIO | TCZ | Prospective registry | 104 | 24- and 48-week EULAR response | | [14] | ORA | TCZ | Prospective registry | 558 | 6-month EULAR response | | [15] | BSRBR | RTX | Prospective registry | 540 | 6-month EULAR response and HAQ improvement | | [16] | Klaasen | IFX | Prospective cohort | 89 | 16-week DAS28 variation | | [17] | GISEA | IFX, ADA, ETN | Prospective registry | 641 | 12-month DAS28 remission | | [19] | Abhishek | IFX, ADA, ETN | Retrospective case control study | 395 | 3-month EULAR response | | [20] | Canhão | IFX, ADA, ETN | Prospective cohort | 615 | EULAR response maintained >3 months in the 1st year | | [21] | EIRA | IFX, ADA, ETN | Prospective cohort | 535 | 3-month EULAR response | | [29] | Chatzidionysiou | RTX | Observational cohort | 2,019 | 6-month EULAR response | | [31] | BSRBR | IFX, ADA, ETN | Prospective registry | 642 | 6-month decrease of DAS28 | | [32] | Maneiro | TCZ, ABA, RTX | Meta-analysis | 23 studies pooled | EULAR and ACR responses | | [39] | Jamnitski | ETN | Cohort | 89 | 28-week DAS28 variations | | [41] | Cui | IFX, ADA, ETN | Nine RA cohorts | 1,283 | EULAR response | | [42] | Plant | IFX, ADA, ETN | Cohort | 1,115 | 6-month EULAR response | | [43] | Plant | IFX, ADA, ETN | Cohort from wellcome trust case control consortium + 2 replication cohorts | 566 (+379 and 341) | 6-month DAS28 variations | | [44] | SMART | RTX | Randomized open trial | 111 | 24-week EULAR response | | [45] | Quartuccio | RTX | Cohort | 212 | 4- and 6-month EULAR response | | [48] | Kayakabe | IFX, ADA, ETN | Prospective open study | 48 | 24-week EULAR response | | [49] | Wijbrandts | IFX | Cohort | 149 | 16-week DAS28 variations | | [52] | RISING | IFX | Double-blind randomized trial | 327 | 54-week DAS28 variation and ACR responses | | [53] | Hueber | ETN | Three different cohorts | 29 + 43 + 21 | ACR responses | | [54] | RADIATE, OPTION, TOWARD, AMBITION and LITHE | TCZ | Five phase 3 trials | 3,143 | 16-week DAS28 variations | | [57] | SMART | RTX | Randomized open label | 208 | 24-week EULAR response | | [61] | Scarsi | ABA | Cohort | 32 | 6-month remission |
|
|
